Background: Daily oral preexposure prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition. Tenofovir has in vitro activity against herpes simplex virus type 2 (HSV-2). (ClinicalTrials.gov: NCT00557245) Setting:Multiple sites in Kenya and Uganda.

READ FULL ARTICLE Curated publisher From Annals